QTTB · Q32 Bio Inc. · Financials
Market Cap
$331.63M
Shares
29.77M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$53.74M
FY2025
Net Income
$29.82M
+162.5%
FY2025
Operating Margin
31.45%
FY2025
Diluted EPS
$2.42
+136.8%
FY2025
Operating Cash Flow
-$33.54M
+50.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| — | $53.74M | $0 | -$6.65M | $3.21M | $33.97M | $2.7M | $1.67M | $3.68M | — | |
| $1.27M | $1.06M | $2.83M | $693K | — | — | — | — | — | — | |
| $14.35M | $19.16M | $48.14M | $31.73M | $98.35M | $93.09M | $100.39M | $89.4M | $47.95M | $21.38M | |
| $17.93M | $17.68M | $17.96M | $9.88M | $38.14M | $36.84M | $32.57M | $22.21M | $17.3M | $8.28M | |
| — | — | — | $10.28M | — | — | — | — | — | — | |
| $32.28M | $36.84M | $66.1M | $41.6M | $136.49M | $129.92M | $132.97M | $111.61M | $65.25M | $29.66M | |
| $21.46M | $16.9M | -$66.1M | -$48.26M | -$133.28M | -$95.95M | -$130.26M | -$109.94M | -$59.93M | -$29.66M | |
| — | 31.45% | — | — | -4154.64% | -282.44% | -4820.98% | -6599.22% | -1626.66% | — | |
| $12.33M | $12.92M | $20.02M | -$5.17M | $134.48M | $185K | $1.57M | $6.03M | $4.35M | -$334K | |
| — | $0 | -$1.63M | $0 | — | — | — | — | — | — | |
| — | $29.82M | -$46.09M | -$87.08M | $1.2M | -$95.76M | — | — | — | — | |
| $0 | $0 | $21K | $318K | $715K | $0 | $0 | $0 | $0 | $0 | |
| -$8.95M | $29.82M | -$47.73M | -$53.74M | -$5.01M | -$95.76M | -$128.69M | -$103.92M | -$55.58M | -$29.99M | |
| — | 55.49% | — | — | -156.02% | -281.9% | -4762.92% | -6237.45% | -1508.6% | — | |
| $3.99M | $29.82K | -$47.73K | -$53.74K | — | — | — | — | — | — | |
| — | $29.82M | -$47.73M | -$53.74M | -$5.4M | -$95.77M | -$128.88M | -$103.66M | -$55.58M | -$30.06M | |
| USD/shares | $3.12 | $2.42 | -$5.12 | -$153.96 | -$1.62 | -$31.14 | — | — | — | — |
| USD/shares | $3.12 | $2.42 | -$6.58 | -$153.96 | -$1.62 | -$31.14 | — | — | — | — |
| shares | — | 12.3M | 9.32M | 349.06K | 3.19M | 3.07M | 2.55M | 2.34M | 1.59M | 137.75K |
| shares | — | 12.31M | 9.66M | 349.06K | 3.19M | 3.07M | 2.55M | 2.34M | 1.59M | 137.75K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 6.58×
EV/EBIT
—
Peer median 9.33×
P/E (TTM common income)
83.02×
Peer median 9.74×
Peer medians compare against the 318 similar-size Biotechnology companies (of 537 listed).
Valuation over time computed as of each quarter's filing date
Key facts
CIK
1661998
CUSIP
746964105
13F (30d)
51 filings
51 filers
Visit website
Investor relations